(Tiper Stock Exchange) – Sanofia French pharmaceutical group, stated that the International Chamber of Commerce ruled in its favor, rejecting Boehringer Ingelheim’s claim for damages arising from the Zantac litigation in the United States. The decision is final and cannot be appealed, reads a statement.
Sanofi is also said “confident” that the defense of the underlying US litigation Zantac “is very strong”. “There is no reliable scientific evidence that Zantac causes the alleged injuries in cases brought against GSK, Pfizer, BI, Sanofi and others in US litigation,” it points out.
The announcement pushes upwards Sanofiwhich stands at 96.91 euros, with a 2.56% increaseand it turns out the mile title of the CAC 40. Operationally, expectations are for a continuation of the day in a positive direction with resistance seen at 97.27 and subsequent at 98.08. Support at 96.46.